NCCN task force report: molecular markers in leukemias and lymphomas

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Targeted therapies have transformed leukemia and lymphoma treatment, yet relapse remains a challenge due to persistent malignant cells.
• Minimal residual disease (MRD) detection is crucial for assessing treatment effectiveness and predicting patient outcomes.
• Advances in molecular techniques are enhancing the ability to identify and quantify MRD.

Purpose of the Study:

• To review recent advancements in molecular markers for MRD detection in leukemias and lymphomas.
• To discuss the role of novel molecular markers in predicting outcomes and guiding treatment strategies.
• To highlight the importance of MRD monitoring in managing hematologic malignancies.

Main Methods:

• Review of current cytogenetic and molecular techniques for MRD assessment.
• Identification and analysis of novel molecular markers, including gene expression signatures and microRNAs.
• Discussion of expert panel findings and recommendations from the National Comprehensive Cancer Network (NCCN).

Main Results:

• Emerging molecular markers show significant potential for MRD detection and prognostication in various leukemias and lymphomas.
• Gene expression signatures can predict clinical outcomes in non-Hodgkin's lymphoma.
• MicroRNAs are identified as potential biomarkers for diagnostics and prognostication.

Conclusions:

• Molecular monitoring of MRD is essential for optimizing treatment and managing resistance in leukemias and lymphomas.
• Novel molecular markers and advanced technologies are improving the precision of MRD assessment.
• Expert consensus emphasizes the growing importance of MRD detection for improved patient care in hematologic malignancies.